Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry2014 · 49 citations
2. 2Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial2008 · 1,057 citations
3. 3Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial2014 · 154 citations
4. 4Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events2016 · 62 citations
5. 5Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus2014 · 39 citations